SCHEMBL2364245

SCHEMBL2364245

Cn1cc(-n2ccc(=O)c(Cc3cccc(N4CCOC4=O)c3)n2)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 2/20 0.42
CDK8 P49336 2/20 0.42
HTR1A P08908 2/20 0.40
HTR1D P28221 2/20 0.40
HTR1B P28222 2/20 0.40
DRD2 P14416 1/20 0.40
HTR2A P28223 1/20 0.40
HTR7 P34969 1/20 0.40
DRD3 P35462 1/20 0.40
HTR2B P41595 1/20 0.40
HTR6 P50406 1/20 0.40
KCNH2 Q12809 1/20 0.40
KCNJ1 P48048 2/20 0.37
IRAK4 Q9NWZ3 3/20 0.34
PDE10A Q9Y233 1/20 0.34
PDE1A P54750 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE1C Q14123 1/20 0.34
IDH1 O75874 1/20 0.33
IRAK1 P51617 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2222113 0.84 PARP1 (0.49) CCNCCDK8HTR1AHTR1DHTR1B
SCHEMBL173258 0.82 PARP1 (0.38) PARP1MEN1KMT2AENPP2
SCHEMBL2221117 0.81 LMNA (0.42) HTR1AHTR1DHTR1BDRD2HTR2A
SCHEMBL13465630 0.81 FYN (0.45) MEN1KMT2AENPP2
SCHEMBL2223676 0.80 ENPP2 (0.42) ENPP2
SCHEMBL2274025 0.80 ENPP2 (0.34) MEN1KMT2AENPP2
SCHEMBL13275216 0.77 CREBBP (0.38) IRAK4IRAK1KMT2A
SCHEMBL2223595 0.77 CREBBP (0.43) IDH1
SCHEMBL13274579 0.77 CCNC (0.41) CCNCCDK8IRAK4
SCHEMBL13275592 0.77 CYP19A1 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US claimed
EP-2515657-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-31 EP disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO disclosed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 CCNC 536/4885CDK8 191/4885HTR1A 2757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.